Clinical trial
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
NCT00434109 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00434109 |
|---|---|
| Title | Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization |
| Official title | Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastrointestinal Neuroendocrine Tumors |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumor, Islet Cell Tumor |
| Intervention type | Drug, Procedure |
| Interventions | Sunitinib malate, Hepatic Artery Embolizations |
| Enrollment | 39 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Feb 12, 2007 |
| Last update posted | Sep 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: